Clinical Trial Detail

NCT ID NCT03012477
Title CISPLATIN + AZD-1775 In Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Adavosertib + Cisplatin

Age Groups: senior adult

No variant requirements are available.